Compare Hims and Hers Health Inc (HIMS) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Jones Lang LaSalle Inc — how do they compare? Hims and Hers Health Inc trades at $28.43 (market cap $6.55B), while Jones Lang LaSalle Inc trades at $303.6 (market cap $13.95B). The key difference: Jones Lang LaSalle Inc is far larger — about 2.1× Hims and Hers Health Inc's market cap, and Jones Lang LaSalle Inc is more actively traded (457,462 versus 14,842,814). Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Jones Lang LaSalle Inc for 71 Days on average.
| HIMS | JLL | |
|---|---|---|
Market Cap | $6.55B | $13.95B |
Volume | 14,842,814 | 457,462 |
Sector | Health | Real Estate |
52-Week High | $62.76 | $392.79 |
52-Week Low | $14.52 | $280.16 |
Typical Hold Time | 21 Days | 71 Days |
Enterprise Value | $7.25B | $16.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $29.54, up slightly by 0.24% on the day. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators remain neutral. Fundamentally, the company reported revenue of $2.35 billion in 2025 but swung to a net loss of $142 million in 2026, with a negative net margin of 5.51%. Analyst consensus is a 'Hold' with a price target of $32.17, but the stock faces significant headwinds from multiple securities class action lawsuits announced in early October 2026.
The outlook for HIMS is clouded by legal risks and profitability challenges despite revenue growth. Investment opportunity hinges on the company's ability to return to profitability and resolve regulatory scrutiny. Key risks include ongoing litigation, FTC complaints, and execution missteps in a competitive telehealth market. Wall Street remains cautious with 65% of analysts recommending Hold.
JLL trades at $296.66, down 2.29% over 24 hours, with a bearish technical signal from moving averages and oscillators. The stock shows strong fundamentals with a P/E of 14.54, P/S of 0.53, and net income margin of 3.64%. Recent earnings have consistently beaten expectations, and cash flow from operations reached $1.19 billion in 2025. Analyst consensus is bullish with a $450.50 price target, supported by positive news on acquisitions and growth prospects.
The outlook for JLL is positive due to robust earnings growth, improving profit margins, and strategic acquisitions. Risks include market volatility, competitive pressures in real estate services, and economic sensitivity. Institutional sentiment remains strong, with a majority of analysts recommending buy. The stock presents a value opportunity if it can sustain its operational momentum amid broader market headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
